Compare Novo Nordisk A/S (NVO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs United States Natural Gas Fund — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while United States Natural Gas Fund trades at $10.41. The key difference: Novo Nordisk A/S pays a 3.63% dividend while United States Natural Gas Fund pays none, and Novo Nordisk A/S is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| NVO | UNG | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Commodities - Energy |
52-Week High | $71.70 | $16.90 |
52-Week Low | $35.29 | $10.15 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
UNG trades at $10.29, down 2.09% today, with a bearish technical signal driven by moving averages. The ETF tracks natural gas futures, facing volatility from weather and LNG demand shifts. Recent news highlights comparisons with equity-based natural gas ETFs like FCG, emphasizing UNG's direct exposure to Henry Hub spot prices.
Outlook remains tied to natural gas market dynamics, with risks from storage reports and production levels. Investment appeal hinges on commodity price speculation, but high volatility and lack of traditional fundamentals limit suitability for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
